Ovid Therapeutics (OVID) EPS (Basic) Growth (1y) (2017 - 2026)
Ovid Therapeutics (OVID) EPS (Basic) Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | 29.25% |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.58 Bn | 466.79 Bn | 1.35 Bn | 17,151.81% |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 61.34% |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn | -7.74% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.80 Bn | 50.61 Bn | 1.41 Bn | 88.81% |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 1,201.33% |
| 10 | Ovid Therapeutics | 120.41 Mn | -35.11 Mn | - | 32.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.62% |
| Dec 31, 2025 | 105.75% |
| Sep 30, 2025 | -208.16% |
| Jun 30, 2025 | -291.37% |
| Mar 31, 2025 | -204.55% |
| Dec 31, 2024 | -806.93% |
| Sep 30, 2024 | -23.84% |
| Jun 30, 2024 | 168.30% |
| Mar 31, 2024 | 12.72% |
| Dec 31, 2023 | -32.89% |
| Sep 30, 2023 | 6.22% |
| Jun 30, 2023 | 15.12% |
| Mar 31, 2023 | 17.26% |
| Dec 31, 2022 | 57.60% |
| Sep 30, 2022 | -1.39% |
| Jun 30, 2022 | 10.98% |
| Mar 31, 2022 | -108.60% |
| Dec 31, 2021 | -2.23% |
| Sep 30, 2021 | 98.32% |
| Jun 30, 2021 | 98.84% |